A supplement label states how much of an ingredient is in the product. It does not show how much will be absorbed systemically, how the compound will behave across the digestive tract, or whether performance will hold through shelf life.
For formulators, that gap is decisive. A promising bioactive can still fail oral delivery because of poor aqueous solubility, slow dissolution, instability, or extensive metabolism – and the dominant constraint varies by ingredient.
From ingredient potential to formulation performance
Pharmaceutical development has long recognized that formulation design governs compound release, absorption, and in vivo performance.¹ Nutrition innovation, by contrast, has centered on ingredient discovery, declared active content, and supporting evidence. These foundations remain essential, but supplement formulation is now a key driver of product success.
Oral delivery of bioactive food compounds is a connected sequence: dissolution in gastrointestinal fluids, gut stability, mucosal absorption, and post-absorptive metabolism.² Optimizing one step does not automatically resolve the others. Nor do favorable laboratory solubility or dispersion results guarantee higher systemic exposure or measurable human benefit.
Four ingredients illustrate the challenge: urolithin A, fisetin, curcumin, and magnesium glycinate.
Four ingredients, four bottlenecks
Urolithin A attracts strong interest in healthy aging, with human trials evaluating safety, pharmacokinetics, and biological effects.³ Its very low aqueous solubility complicates conventional oral dosage forms; the manufacturing approach directly affects particle dispersion and gastrointestinal dissolution.⁴
Fisetin, a dietary flavonoid, has preclinical potential in cellular senescence and health-span research.⁵ Poor water solubility and limited oral bioavailability restrict standard delivery. Like many polyphenols, fisetin undergoes extensive phase II metabolism – including glucuronidation and sulfation – reshaping circulating molecular forms.⁶
Curcumin remains a best-selling nutraceutical active, but severe hydrophobicity, negligible aqueous solubility, pH-driven instability, and extensive first-pass metabolism produce low curcumin bioavailability and a poor relationship between label dose and plasma levels.⁷,⁸
Magnesium glycinate is a premium chelated mineral favored for gastrointestinal tolerance and relative bioavailability versus inorganic salts.⁹
Its challenge is physical: as a polar, salt-like powder, it is typically handled as a hygroscopic material, requiring moisture control during blending and filling, which can create weight-fill variability. Developers must balance elemental magnesium content with manufacturability, shelf-life stability, and compatibility in powders, sachets, and beverages.
Together, these ingredients show why no single delivery technology can solve every biochemical limitation. Raising the label dose is rarely effective: it increases raw-material cost and serving size, complicates dosage-form engineering, and often leaves the absorption bottleneck intact.
Why delivery technology must start with the ingredient
Poor water solubility is a common entry point for delivery discussions, but not a sufficient basis for choosing a technology. Two compounds with similar solubility can differ substantially in stability, permeability, and metabolism – and therefore in what they need.
The first step is to identify the dominant constraint:
- Is the ingredient hard to disperse in water?
- Does it dissolve slowly?
- Is it vulnerable to degradation during processing or storage?
- Or does the limitation occur after absorption?
The answer dictates which delivery technologies merit evaluation and which analytical testing is required. Terminology can mislead. A water-dispersible formulation may suit a powder or beverage, but dispersibility alone does not establish better absorption. Smaller particles may influence dissolution, but particle size is not evidence of greater bioavailability.
A robust development workflow links measurable formulation characteristics to end-use performance: particle-size distribution, dissolution profiles, physicochemical stability, excipient compatibility, manufacturing reproducibility, and comparative pharmacokinetic data.
Ingredient-specific formulation solutions
BonFusion™ addresses ingredient-specific challenges rather than applying one carrier across a portfolio. Development starts with the ingredient’s physicochemical properties and the intended finished-product format. Options are then assessed against defined performance requirements: dispersion, dissolution, physical stability, ingredient loading, and manufacturing compatibility.
This matters commercially. A formulation that excels in a laboratory dispersion test may struggle in tablet compression, capsule filling, storage, or a beverage. The question is not only whether a delivery system can be made, but whether its performance holds under finished-product conditions.
BonFusion™ is advancing delivery solutions for four priority ingredients: fisetin, urolithin A, curcumin, and magnesium glycinate.
For urolithin A and fisetin, the shared challenge is high lipophilicity plus extremely low water solubility, which suppresses dissolution and oral absorption.¹⁰ Higher label doses cannot overcome these physiological barriers or guarantee systemic exposure.
BonFusion™ uses complementary enabling technologies to produce lipid-based nanoscale dispersions, approximately 200nm to 300nm. Internal side-by-side testing has shown 3 to 5-fold bioavailability enhancement for these formulations. Good water dispersibility and powder flowability support tablets, hard-shell capsules, sachets, oral liquids, and beverages via a unified platform.
For curcumin, BonFusion™ is developing a water-compatible formulation to improve aqueous compatibility, expand dosage-form options, and mitigate pH-related degradation, with the aim of improving effective exposure.
For magnesium glycinate, BonFusion™ is engineering a water-dispersible formulation to improve powder dispersibility and processability for sachets, oral liquids, and functional beverages while managing hygroscopicity and elemental magnesium loading.
Across these actives, the principle is consistent: identify the dominant formulation barrier, select matched technical approaches, and validate performance against real-world end-application requirements. This translates ingredient-specific pain points into practical, scalable solutions for finished-product manufacturers.
From ingredient supply to supplement formulation partnership
Supplement formulation choices are increasingly tied to product positioning. A capsule brand may prioritize active loading and stability; a powder or beverage brand may prioritize dispersibility, appearance, taste, and physical stability. These needs shape which ingredients fit a product and how easily they can be incorporated.
For suppliers, this creates an opportunity to contribute earlier: helping brands compare formulation options, identify manufacturing constraints, and set performance criteria before committing to a finished-product concept. BonFusion™ is being developed with that role in mind.
The commercial case will rest on evidence: reproducible formulation performance, stability data, scalable manufacturing, and – where enhanced absorption is claimed – suitable comparative pharmacokinetic studies.
For brands planning their next launch, the question is no longer only whether an ingredient has scientific potential. It is whether that ingredient can be delivered in a format that meets technical requirements, supports a credible proposition, and works at scale. That is the problem Bonerge aims to address with BonFusion™.
Future pipeline: Candidate ingredients under market evaluation
Beyond the four active-development projects, Bonerge Lifescience maintains a candidate pipeline for future BonFusion™ adaptations.
Current candidates include:
- Dihydroberberine
- Dihydromyricetin
- Quercetin
- Coenzyme Q10
- Piperine
- PQQ
- Vitamin D3
- Vitamin K2
Each presents recognized formulation hurdles – poor water solubility, stability limitations, challenging sensory profiles, or suboptimal oral bioavailability – that can be addressed through ingredient-specific water-dispersible or water-soluble nanodispersion approaches.
Your feedback will help allocate R&D resources toward the highest-demand solutions.
References
- Park, H.; et al. Evolution of drug delivery systems: From 1950 to 2020 and beyond. J Control Release. 2022; 342:53-65.
- Rein, MJ.; et al. Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. Br J Clin Pharmacol. 2013; 75(3):588-602.
- Andreux, PA.; et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019; 1(6):595-603.
- Esposito, E.; et al. Development of a submicron emulsion-based delivery system to improve the anti-inflammatory activity of urolithin A. J Pharm Pharm Sci. 2025; 28:15553.
- Yousefzadeh, MJ.; et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018; 36:18-28.
- Williamson, G.; et al. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr. 2005; 81(1 Suppl):243S-255S.
- Alshammari EM. Curcumin-based biocompatible nanocarriers: a contemporary perspective in functional foods and biomedical applications. Discov Nano. 2025; 20(1):226.
- Hewlings, SJ.; et al. Curcumin: A Review of Its Effects on Human Health. Foods. 2017; 6(10):92.
- Brilli, E.; et al. Magnesium bioavailability after administration of sucrosomial® magnesium: results of an ex-vivo study and a comparative, double-blinded, cross-over study in healthy subjects. Eur Rev Med Pharmacol Sci. 2018; 22(6):1843-1851.
- Yao, M.; et al. Delivery of lipophilic bioactives: assembly, disassembly, and reassembly of lipid nanoparticles. Annu Rev Food Sci Technol. 2014; 5:53-81.
